

HEALTHCARE MONTHLY

NOVEMBER 2024

Our healthcare team architects market-defining outcomes for some of the most innovative medical device, life science and diagnostics, healthcare services and pharmaceutical companies in the world.

BioTech / Pharma **Healthcare Services** Life Sciences / Diagnostics **Medical Devices**

HEADLINE TRANSACTIONS

ACQUIROR



ACQUISITION SYNOPSIS

- H. Lundbeck A/S (CSE: HLUN A) has entered a definitive agreement to acquire Longboard Pharmaceuticals, Inc. (NASD: LBPH) · Longboard Pharmaceuticals is a clinical-stage biopharmaceutical company developing medicines targeting neurological diseases,
- principally Developmental and Epileptic Encephalopathy syndromes
- H. Lundbeck is a Danish pharmaceutical company developing and commercializing drugs targeting the central nervous system including antidepressants, antipsychotics and antiepileptics
- Total Consideration: \$2.6 billion cash
- Per Share Price Premium: 54.2%



Johnson Johnson



· AbbVie, Inc. (NYSE: ABBV) has entered a definitive agreement to acquire Aliada Therapeutics, Inc. from Johnson & Johnson Innovation, Inc. and a consortium of investors



- AbbVie is a pharmaceutical company discovering and developing medicines targeting immunology, oncology, aesthetics, neuroscience and
- Total Consideration: \$1.4 billion cash





- Merck & Co., Inc. (NYSE: MRK) has entered a definitive agreement to acquire Modifi Biosciences, Inc.
- · Modifi Bio is developing a platform of cancer therapeutics targeting tumor DNA without negatively impacting healthy cells
- Merck is a pharmaceutical and life sciences company developing and producing medicines, vaccines, biologic therapies and animal health products
- Total Consideration: \$1.3 billion cash






- Francisco Partners has entered a definitive agreement to acquire AdvancedMD, Inc. from Global Payments Inc. (NYSE: GPN)
- AdvancedMD is a provider of cloud-based practice management, electronic health records and revenue cycle management services
- · Francisco Partners is a San Francisco-based private equity firm managing \$45 billion of assets; its healthcare investments are primarily focused within IT services, software and healthcare data analytics
- Total Consideration: \$1.1 billion cash






HEALTHCARE GROWTH & VALUATION TRENDS


Enterprise Value / LTM Revenue




Enterprise Value / LTM EBITDA



LTM Revenue Growth




LTM Gross and EBITDA Margins*



*EBITDA Margins shown as the gray line.

LTM Stock Price Index





SELECTED HEALTHCARE TRANSACTIONS

Target	Acquiror	BioTech / Pharma Transactions	Target	Acquiror	Health Services Transactions
Global Rights to Enjaymo" (Sanofi SA (NASD: SNY))	Dr. Reddy's Laboratories Ltd (BOM: 500124)	Enjaymo® is a monoclonal antibody treatment targeting cold agglutinin disease, a rare autoimmune disorder Total Consideration: \$850 million cash; \$250 million earnout	Northern Carolina Fertility Medical Center	IVY Fertility Services, LLC (InTandem Capital Partners LLC)	Northern Carolina Fertility Medical Center provides advanced reproductive technology, in-vitro fertilization and third-party reproduction services to patients in Sacramento, the Bay Area and all over the United States
Orano Med LLC	Sanofi SA (NASD: SNY)	Orano Med is a biotechnology company developing a portfolio of radiopharmaceuticals targeting different cancer receptors / antigensIotal Consideration: \$325 million cash	Elite Sports Medicine & Physical Therapy	Preferred Physical Therapy (Partners Group Holding AG)	Elite Sports Medicine & Physical Therapy provides integrative medicine, personalized nutrition, personal training and physical therapy in Leawood, Kansas
Bio-Vet, Inc	Anpario plc (LON: ANP)	Bio-Vet develops and produces probiotic products including capsules, boluses, pastes and other daily feed additives to improve animal health and nutrition	The Swan Center for Plastic Surgery	United Aesthetics Alliance (Varsity Healthcare Partners, Inc.)	The Swan Center for Plastic Surgery is a plastic surgery center and medical spa providing surgical and non-surgical aesthetic services to patients in the Atlanta metro area
Target	Acquiror	Life Sci / Diagnostics Transactions	Target	Acquiror	Medical Device Transactions
SYNLAB's Clinical Diagnostics Operations in Spain	Eurofins Scientific SE (ENXTPA: ERF)	SYNLAB's clinical diagnostics operations in Spain provide clinical diagnostics testing, including genetics and anatomical pathology services; the segment generated revenues of ~\$150 million in 2023	Gynesonics, Inc.	Hologic Inc. (NASD: HOLX)	Gynesonics develops minimally invasive devices targeting women's health including intrauterine imaging & transcervical treatment devices Total Consideration: \$350 million
BioEcho Life Sciences GmbH (Ampersand Capital Partners)	Admera Health LLC	BioEcho Life Sciences develops and manufactures kits, reagents and biochemical solutions for the diagnostics, human & veterinary medicine and forensics endmarkets	DirectMed Imaging, LLC (NMS Capital LLC)	Frazier Management, LLC	DirectMed Imaging provides aftermarket parts and component repairs for MRI and CT machines
Dynamic Biosensors GmbH	Bruker Corp (NASD: BRKR)	Dynamic Biosensors develops and markets technologies that facilitate the study of complex molecular interactions and kinetics	Ridgeback Technologies Ltd	Quasar Medical (Boyu Capital Management Ltd)	Ridgeback Technologies designs, develops and manufactures a wide range of specialized catheter balloons used in cardiovascular, neurovascular and peripheral medical procedures

Selected TM Capital Healthcare Experience







TM Capital's Healthcare Industry Contacts



James McLaren Managing Director jmclaren@tmcapital.com 212.809.1414



Michael Goldman Managing Director mgoldman@tmcapital.com 212.809.1419



John Dean Director jdean@tmcapital.com 404.995.6234



Paul Smolevitz
Managing Director
psmolevitz@tmcapital.com
212.809.1416



Josh Mastracci Director jmastracci@tmcapital.com 404.924.4562



Steve Hunter Managing Director, Sponsor Coverage shunter@tmcapital.com 404.995.6232

ABOUT TM CAPITAL, A DIVISION OF JANNEY

FOUNDED IN 1989 AND NOW PART OF JANNEY MONTGOMERY SCOTT, TM CAPITAL IS THE CLIENT-FIRST INVESTMENT BANKING TEAM ADVISING INDUSTRY-LEADING COMPANIES ACROSS NORTH AMERICA AND AROUND THE WORLD. IN EVERYTHING WE DO, OUR PROFESSIONALS SHARE A RELENTLESS COMMITMENT TO ENGINEERING EXTRAORDINARY OUTCOMES WITH AN UNMATCHED STANDARD OF CLIENT CARE. OVER THE LAST THREE DECADES, WE HAVE COMPLETED NEARLY 450 TRANSACTIONS WITH A COMBINED VALUE OF \$30 BILLION. WITH OFFICES IN ATLANTA, BOSTON AND NEW YORK, OUR MISSION CRITICAL CAPABILITIES INCLUDE: COMPLEX MERGERS AND ACQUISITIONS; DEBT AND EQUITY FINANCINGS; MINORITY AND MAJORITY RECAPITALIZATIONS; RESTRUCTURINGS; AND BOARD ADVISORY SERVICES. TM CAPITAL IS ALSO A MEMBER OF OAKLINS, THE WORLD'S MOST EXPERIENCED MID-MARKET M&A ADVISOR, WITH OVER 850 PROFESSIONALS AND DEDICATED INDUSTRY TEAMS IN MORE THAN 45 COUNTRIES, HAVING CLOSED 1,700 TRANSACTIONS IN THE PAST FIVE YEARS. FOR MORE INFORMATION, PLEASE VISIT WWW.TMCAPITAL.COM.

ABOUT JANNEY

JANNEY IS A LEADING FULL-SERVICE WEALTH MANAGEMENT, CAPITAL MARKETS, AND ASSET MANAGEMENT FIRM DEDICATED TO PUTTING CLIENT NEEDS FIRST. WE ARE COMMITTED TO PROVIDING INDIVIDUALS, FAMILIES, BUSINESSES, AND INSTITUTIONS WITH TAILORED FINANCIAL ADVICE TO HELP REACH THEIR PERSONAL OR BUSINESS GOALS. WE FOCUS ON BUILDING STRONG RELATIONSHIPS, SUPPORTED BY A FOUNDATION OF TRUST AND PERFORMANCE. WITH A HISTORY OF STRENGTH AND STABILITY, AN ABILITY TO EXECUTE, AND A CULTURE OF SERVICE AND COLLABORATION, WE CONTINUE TO DELIVER ON OUR MISSION OF OFFERING THE HIGHEST STANDARD OF SUCCESS IN FINANCIAL RELATIONSHIPS. JANNEY IS A MEMBER OF THE FINANCIAL INDUSTRY REGULATORY AUTHORITY, THE NEW YORK STOCK EXCHANGE, AND SECURITIES INVESTOR PROTECTION CORPORATION.

THIS COMMUNICATION IS THE INTELLECTUAL PROPERTY OF TM CAPITAL, A DIVISION OF JANNEY AND MAY NOT BE REPRODUCED, DISTRIBUTED, OR PUBLISHED BY ANY PERSON FOR ANY PURPOSE WITHOUT JANNEY'S EXPRESS PRIOR CONSENT.

DISCLAIMER: This communication has been created by the Investment Banking Department of Janney Montgomery Scott LLC ("Janney") and is to be used for informational purposes only. It is not a product of Janney's Research Department. The information presented herein is taken from sources believed to be reliable but is not guaranteed by Janney as to its accuracy or completeness and is subject to change. The views expressed in this communication reflect the personal views of the author(s) regarding the subject securities and issuers and may differ with those of Janney or Janney's Research Department. This communication shall not constitute a solicitation or offer to purchase or sell a security. This communication is intended for Institutional Use Only, not for retail investors, and should not be distributed, forwarded, or otherwise disseminated. Nothing in this material should be construed as tax, legal, or accounting advice. Please consult your own tax, legal, and accounting professionals. Member: NYSE, FINRA, SIPC.